There are currently 44 active clinical trials seeking participants for Brain Metastases research studies. The states with the highest number of trials for Autism participants are Michigan, California, New York and North Carolina.
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT05987644
Recruiting
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Lung Cancer, NSCLC, Brain Metastases
Register for Updates
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
NCT05786924
Recruiting
BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations or BRAF mutations, advanced/metastatic melanom... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Banner Health- MD Anderson Cancer Center, Gilbert, Arizona +8 locations
Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C
Register for Updates
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
NCT06048094
Recruiting
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Miami Cancer Institute, Miami, Florida
Conditions: Brain Metastases, Brain Metastases, Adult, Brain Cancer
Register for Updates
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
NCT05692635
Recruiting
The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Brain Metastases, Nonsmall Cell Lung Cancer Stage III
Register for Updates
REMASTer: REcurrent Brain Metastases After SRS Trial
NCT05124912
Recruiting
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Duke University Hospital, Durham, North Carolina +2 locations
Conditions: Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
Register for Updates
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391
Recruiting
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +83 locations
Conditions: Brain Metastases
Register for Updates
Neurocognitive Decline in Patients With Brain Metastases
NCT03508752
Recruiting
The phase I component of the study is to identify maximal tolerated dose (MTD). The phase II is to evaluate neurocognitive decline.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Brain Metastases
Register for Updates
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
NCT05045950
Recruiting
Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin +1 locations
Conditions: Brain Metastases
Register for Updates
MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases
NCT04246879
Recruiting
The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Duke University Health System, Durham, North Carolina
Conditions: Brain Metastases
Register for Updates
NTS-WBRT in Brain Metastases
NCT05013892
Recruiting
This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: NTS-WBRT (normal tissue sparing whole brain radiation therapy) Memantine standard of care drug
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Brain Metastases
Register for Updates
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
NCT04365374
Recruiting
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: HonorHealth Research Institute, Phoenix, Arizona +22 locations
Conditions: Brain Metastases
Register for Updates
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT05323955
Recruiting
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical resection if indicated followed by enrollment. Patients will continue standard of care trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor positive patients requiring endocrine therapy should con... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +6 locations
Conditions: Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Register for Updates